Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

255P - Predictive factors of distant recurrence disease in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy

Date

17 Sep 2020

Session

E-Poster Display

Topics

Cytotoxic Therapy

Tumour Site

Breast Cancer

Presenters

Jose Ponce

Citation

Annals of Oncology (2020) 31 (suppl_4): S340-S347. 10.1016/annonc/annonc260

Authors

J. Ponce1, A. Rodriguez-Lescure2, S. Delgado3, G. Peiró4, M. Pastor-Valero5, M. Reche6, I. Lozano1, B. Massuti Sureda1

Author affiliations

  • 1 Medical Oncology Department, University General Hospital of Alicante, 03010 - Alicante/ES
  • 2 Medical Oncology Department, University General Hospital of Elche, 03203 - Elche, Alicante/ES
  • 3 Obstetrics And Gynecology Department, University General Hospital of Alicante, 03010 - Alicante/ES
  • 4 Pathology Department, University General Hospital of Alicante, 03010 - Alicante/ES
  • 5 Public Health, History Of Science And Gynaecology, Faculty of Medicine, Miguel Hernández de Elche University. CIBER in Epidemiology and Public Health (CIBERESP), Sant Joan d'Alacant/ES
  • 6 Radiology Department, University General Hospital of Alicante, 03010 - Alicante/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 255P

Background

Patients with breast cancer achieving a pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) have a favourable outcome. However some patients may relapse. Identifying subgroups that have a potential risk of recurrence in this context is essential. The purpose of this study was to identify predictive factors for distant recurrence disease.

Methods

Patients with operable or locally advanced breast cancers treated with NACT in a single institution. pCR was defined as absence of residual invasive cancer in the primary tumour and axillary lymph nodes at surgery. Kaplan-Meier method was used for estimating the DDFS curves, the log rank test was performed to compare the curves and Cox’s proportional hazards model was used to assess the effect of potencial predictive factors for distant disease free survival (DDFS).

Results

537 patients with breast cancer received NACT from 1998 to 2018. Median follow-up was 64,5 months. 119 achieved a pCR (22,2%). Of them, 11 (9,2%) presented an event of interest for DDFS analyses. Five-year DDFS was 91,6%. Predictors for DDFS in univariate analysis were cT stage (χ2=45.408, p<0.001), AJCC Anatomic Stage Groups (χ2= 110,784, p<0.001), and AJCC Clinical Prognostic Stage Groups (χ2= 22,868, p=0.001). In the multivariate analyse only AJCC anatomic stage groups retained significative results for DDFS (p<0,001).

Conclusions

In our study, after pCR in breast cancer patients treated with NACT, only AJCC anatomic stage groups was significant for DDFS in the multivariate analyse. In this special population, these results emphasize the importance of meticulous staging at diagnosis and suggest the possibility of personalised follow-up and modulated adjuvant treatment after surgery based on AJCC anatomic stage groups.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.